Clomiphene QB
Related Articles
Unrivaled Brands Inc (OTCQX:UNRV) announced its second quarter financial results, showing significant year-over-year revenue and gross margin growth. The West Coast cannabis company generated total revenue of $17.56 million in the three months ended June 30, including retail revenue of $10.95 million and cultivation revenue /distribution of $6.61 million. That’s more than six times the $2.87 million in revenue earned during the same period of 2021, including $2.32 million in retail revenue. Gross profit was $8.27 million, more than triple the profit of $2.72 million a year ago.
Dore Copper Mining Corp announced that it had appointed Nicholas Kwong, a 15-year mining industry veteran, as chief operating officer effective immediately. Kwong’s experience in the mining industry has been largely in gold and base metals in North America, Australia, Latin America and Saudi Arabia. He held numerous site and corporate positions for New Gold, including Technical Services Manager, and then joined Ma’aden Gold in Saudi Arabia as General Manager of the Sukhaybarat and Bulghah Gold Mines.
Nextech AR Solutions Corp released its financial and operating results for the second quarter ending June 30, 2022, showing continued record growth in 3D modeling for e-commerce and its Web3.0 business. The augmented reality (AR) solutions provider said Web3.0 and 3D modeling revenue grew 40% quarter over quarter in the three months to June 30, 2022. It said added that annual recurring revenue and recurring revenue was $1.6 million, also a record for the company. Looking to the third quarter, Nextech said its newly implemented service action plan will reduce its monthly consumption from approximately $1 million per month to approximately $500,000 per month, extending its cash trail for at least 12 months.
Westwater Resources Inc (NYSE-A:WWR) has applauded the landmark Cut Inflation Act signed into law by President Joe Biden on August 16, 2022, which includes a $369 billion investment in climate programs that should, directly and indirectly, benefit Westwater. In a statement, Terence Cryan, executive chairman of Westwater, said: “Our company is in a unique position to benefit from this legislation. The legislation provides direct benefits in the form of a production tax credit for future production of advanced anode materials from our Kellyton graphite plant. In addition, the legislation is expected to increase demand for domestically produced graphite and vanadium, both contained in our Coosa graphite deposit – The IRA is good news for Westwater. The main provision that directly benefits Westwater is the Critical Minerals Production Tax Credit, which provides a 10% tax credit for the production costs of certain critical minerals, including graphite and vanadium.
Universal Ibogaine Inc (TSX-V:IBO) said it is aiming for the reopening of its Winnipeg substance abuse treatment center, the Kelburn Recovery Center, in early October after it closed in April due to damage from a drug back-up. sewer on site. Before repairs could be completed, abnormally high spring rainfall and snowmelt runoff caused the Red River to flood, forcing local road closures, but no further damage to the facility. . Repairs are now underway and proceeds receivable under Kelburn’s insurance coverage are being finalized. The company said it was developing a best-in-class, evidence-based, holistic addiction recovery program to offer at the Kelburn facility which, upon Health Canada approval, may involve ibogaine: a plant-derived drug used in the treatment of drug addiction and has been shown to provide detoxification from opioids, heroin, and other substances, and can provide several months of drug cravings.
PharmaDrug Inc (CSE: PHRX, OTCQB: LMLLF) said it has completed significant preparatory work to support the production of several kilograms for use in the final production of the drug PD-001, its patented oral version of cepharanthin, to treat reactive cancers and COVID-19. Completion of this batch, scheduled for September 2022, advances PharmaDrug’s plans toward potential Phase 2 clinical studies. PharmaDrug has engaged Genvion Corporation to perform stability testing and forced degradation studies in support of future Investigational New Drug (IND) filings with the United States Food and Drug Administration (FDA).
CleanSpark Inc (NASDAQ:CLSK) announced that it has completed the acquisition of an active bitcoin mining facility located in Washington, Georgia. Sustainable mining and energy technology company Bitcoin said the site is expected to add 2.6 exahashes per second (EH/s) to CleanSpark’s hashrate once the 86 megawatts (MW) of mostly carbon-free energy is fully operational in 2023. tremendous opportunity for CleanSpark and our shareholders and we are excited to move forward so quickly on the rollout of this site,” CleanSpark Executive Chairman Matt Schultz said in a statement.
Aion Therapeutic Inc said it plans to late file its audited annual consolidated financial statements and related annual MD&A for the fiscal year ended April 30, 2022, by the prescribed deadline of August 29, 2022. On August 10, 2022, the firm changed its auditors from Harborside CPA LLP to Kreston GTA LLP. Due to the change of the issuer’s auditor so close to the filing deadline, the company and the auditor need more time to file the annual financial statements and the management report. The Company anticipates that it will be able to file the annual financial statements and related MD&A no later than October 31, 2022. Accordingly, the Company has filed an application with the relevant securities authorities under the Policy 12-203 — Cess Continuous Disclosure Failures Trade Orders requesting that a management cease trade order be imposed with respect to the early late filing rather than a cease trade order. issuer operations. The issuance of a management cease trade order does not affect the ability of persons who have not been directors, officers or insiders of the Company to trade in their securities.
Kootenay Silver Inc clarified that a press release issued on August 12, 2022, entitled “Kootenay Resources Inc. Announces Private Placement Financing of Up to $800,000” relates to Kootenay Resources Inc, a private reporting issuer and is not not related to the common shares of Kootenay Silver, a company listed on the TSX Venture Exchange. Kootenay Resources is an exploration company actively engaged in exploration and discovery mining projects in British Columbia, Canada. The transaction was completed in October 2021, Kootenay Silver currently owns approximately 3.2 million common shares of Kootenay Resources.
Wishpond Technologies Ltd said the TSX Venture Exchange has agreed to file the company’s proposal to issue 283,677 common shares of the company at a deemed price of 59.7 cents per share in consideration for earnout payments to AtlasMind Inc., as set forth in Asset Purchase Agreement dated August 27, 2021. The stock exchange has also agreed to file the company’s proposal to issue a total of 1,076,405 shares at a deemed price of 64, 42 cents per share in consideration for earnout payments to owners of PersistIQ, as set forth in the share purchase agreement dated February 26, 2021.
Usha Resources Ltd (TSX-V:USHA) has announced that Deepak Varshney, its CEO, will present live on VirtualInvestorConferences.com on August 23, 2022 at 1:30 p.m. PDT/4:30 p.m. EDT via the following link: https://bit .ly/3JSF8GE . This battery metals-focused event is co-sponsored by Virtual Investor Conferences and Independent Investment Research LLC. If attendees are unable to join the live event on the day of the conference, an archived webcast will also be available after the event.
Todos Medical Ltd has announced that its majority-owned joint venture 3CL Pharma Ltd has announced the pre-publication in ResearchGate of the results of the first 100-participant study of an IRB-medicated market study titled “The Value of Protease Inhibitor Supplementation 3CL in patients with long distance syndrome? supervised by Dr. Dorit Arad in concert with Andrew Blumenthal, CEO of Todos. Study participants are primarily patients with post-acute sequelae of COVID as well as participants with acute COVID infection. Results to date indicate that participants appear to experience benefits after supplementation with the 3CL protease inhibitor immune support supplement Tollovid. The preprint of the publication can be viewed here.
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has announced that it has updated its corporate slideshow which, among other initiatives, outlines its plans to advance the development of its psilocin analogues L-130 and L-131. Philip Young, CEO of Lobe Sciences, said, “We have made significant progress towards initiating our first-in-human trials with our proprietary psilocin analogue L-130 and our preclinical plans for L-131. These updates are available on our company website at https://www.lobesciences.com/corporate-profile/company-presentation/ We believe that Lobe is beginning to be recognized as one of the leading companies developing stable psilocin compounds as reported in leading biotech publications such as Fierce Biotech. an exciting time for all stakeholders and I look forward to continuing to update the investment community as we move forward with our plans to develop new medicines for patients around the world. »
Vyant Bio (NASDAQ:VYNT) Inc announced that it will release its financial results for the second quarter and first six months ended June 30, 2022 on Monday, August 22, 2022. Vyant Bio (NASDAQ:VYNT) will host a conference call with investors and webcast on Monday, August 22, 2022 at 4:30 p.m. ET. Jay Roberts, CEO, Andy LaFrence, CFO, and Robert Fremeau, CSO, of Vyant Bio (NASDAQ:VYNT) will provide an update on the business, scientific and financial progress made during the second quarter and first half of 2022. Management will also respond to questions from the public submitted in advance only. Investors may submit written questions by email to: info@skylineccg.com. Participants can dial 1-877-545-0523 using conference ID: 46428. A webcast will be available at https://www.webcaster4.com/Webcast/Page/2756/46428. The event will be recorded and available for replay. Details of the conference call and webcast are also included in the Investors section of Vyant Bio’s corporate website at www.vyantbio.com.
